Aims: To assess the effects on glycaemic control of lixisenatide vs placebo as add-on treatment to basal insulin (BI) AE metformin and effects on glycated haemoglobin (HbA1c) reduction in patients with insufficiently controlled type 2 diabetes (T2D).
manual labour and physical activity) and urbanization (an increase in the urban population driven by rural to urban migration). [1] [2] [3] [4] [5] In addition to these environmental influences, there may also be a genetic predisposition to T2D in the Asian population. 6 In China, T2D is undertreated; a cross-sectional survey in 2010 revealed that only 26% of patients received treatment for diabetes and only 40% of those treated had adequate glycaemic control within guideline ranges. 1, 7, 8 Despite guidance provided by diabetes treatment algorithms, glycaemic control targets are not always achieved for those patients who receive treatment; therefore, further treatment options are required in this population with T2D. shown to improve glycaemic control in Asian populations. 11, 12 Lixisenatide (Sanofi, Paris, France/Bridgewater, New Jersey) is a once-daily, short-acting, selective GLP-1 RA, approved for use in >60
countries, including countries in Europe, the USA, South Korea and Japan
(not yet approved in China), with oral glucose-lowering agents and/or BI in the treatment of adults with T2D when the use of these agents with diet and exercise has provided inadequate glycaemic control. 13 Lixisenatide has been evaluated in a series of trials (the GetGoal clinical trial programme) as monotherapy, in combination with oral antidiabetic drugs (OADs) and as add-on therapy to BI. [14] [15] [16] [17] [18] [19] [20] [21] [22] GetGoal-L, which enrolled a global population with T2D, and
GetGoal-L-Asia, were double-blind, parallel-group, placebo-controlled trials investigating the effects of lixisenatide added to BI. 18, 22 The present trial, GetGoal-L-C, follows a similar design but investigates a more targeted population with the objective of assessing the efficacy and safety of lixisenatide compared with placebo as an add-on treatment to BI with or without metformin after an 8-week treat-to-target optimization of established therapy with BI. The study was performed in Asian patients (predominantly from China) with inadequately controlled T2D over a period of 24 weeks.
| METHODS

| Trial design
This was a phase III, double-blind, 1:1 randomized, placebo-controlled, two-arm parallel-group, multicentre, multinational study over 
| Trial population
Adults with T2D diagnosed ≥1 year before the screening visit were eligible for inclusion if they had glycated haemoglobin (HbA1c) ≥7% 
| Randomization and interventions
Patients were randomized (1:1 through an interactive voice response system/interactive web response system which allocated the patient treatments) to either lixisenatide or placebo once daily during the randomized, double-blind treatment period and were stratified at randomization by HbA1c (<8%, ≥8%) at visit 9 (week −1) and metformin use (yes/no) at screening.
During the 8-week run-in phase, existing BI was optimally titrated to a target SMPG of 4.4 to 5.6 mmol/L (Table S1 , Appendix S1). At the end of run-in, eligible patients (HbA1c ≥7% and ≤9.5%, fasting SMPG ≤7.8 mmol/L) entered the 24-week randomized, double-blind treatment phase, during which the optimized BI was to be kept stable. A 3-day safety follow-up period followed permanent study treatment discontinuation ( Figure 1 (Table S2, Appendix S1), patients were withdrawn from the study.
| Study endpoints
The primary efficacy endpoint was the absolute change in HbA1c from baseline to week 24. Secondary efficacy endpoints included:
percentage of patients reaching the HbA1c target of <7% or ≤6.5% 
| Statistical analyses
The efficacy analysis population was the modified intention-to-treat variables change from baseline to week 24: 2-hour PPG, FPG, daily average of 7-point SMPG, BW and total daily insulin dose. For the primary efficacy variable, differences between lixisenatide and placebo and associated 2-sided 95% confidence intervals (CIs) were estimated using ANCOVA. An ANCOVA model was also applied on continuous secondary efficacy endpoints and all categorical efficacy endpoints were analysed using a Cochran-Mantel-Haenszel method stratified by randomization strata. In cases of premature discontinuation of the double-blind treatments, efficacy variables were assessed at the time of treatment discontinuation. For week 24 analyses, the last observation carried forward procedure was used by identifying the last available post-baseline measurement in the on-treatment period as the week 24 value. AEs were summarized using descriptive statistics.
3 | RESULTS
| Population characteristics
Overall, 789 patients were screened; 597 entered the run-in phase (149 patients failed the run-in phase, most commonly [12. 7%] because of HbA1c levels outside of the predefined range) and 448 patients from four countries were randomized (Table 1 and Figure S1 , Appendix S1), with 224 patients in each group. was permitted, instead a stopping rule was implemented (Table S2 , Appendix S1).
Baseline demographics and characteristics were similar across treatment groups (Table 1) ; >50% of patients were from China. a Lixisenatide n = 224; placebo n = 223. and the LS mean (s.e.) difference for lixisenatide vs placebo was −0.51 (0.09)% (95% CI −0.685, −0.341; P < .0001; Figure 2A ). This improvement in HbA1c was also reflected in the greater proportion of patients achieving HbA1c targets <7% or ≤6.5% at week 24 with lixisenatide vs placebo (P < .0001; Figure 2B ).
| Primary efficacy endpoint
| Secondary efficacy endpoints
During the run-in period, after titration of BI, the daily dose increased Table 2 ) and 2-hour PPG (−3.45 mmol/L; P < .0001; Table 2 ) compared with placebo.
After 24 weeks, values on the 7-point SMPG profiles were lower at all timepoints in the lixisenatide group compared with placebo, with the exception of pre-breakfast values, which were similar for both groups. The LS mean difference in mean 7-point SMPG values was statistically greater for the lixisenatide group compared with the placebo group (P = .0014; Table 2 ).
The superior improvement in glycaemic control was not associated with a negative impact on BW: lixisenatide led to a significant mean reduction in BW (−1.12 kg) from baseline to week 24, which was superior compared with placebo (0.04 kg; P < .0001; Figure S2 , Appendix S1). The mean difference in BI total daily dose from baseline to week 24 was significantly greater for lixisenatide vs placebo (LS mean difference −1.1 U; Table 2 ).
| Adverse events
Safety and tolerability data (Table 3) were consistent with the established safety profile of lixisenatide. Nausea, vomiting and decreased appetite were more frequent with lixisenatide than with placebo.
There were no deaths during the study. No cases of pancreatitis (adjudicated by the Pancreatic Safety Assessment Committee) or confirmed increase in lipase/amylase or blood calcitonin increase were reported.
In the lixisenatide group TEAEs were more frequent than in the placebo group (Table 3) ; the difference was predominantly attributable to metabolic and GI TEAEs, which were primarily nausea and vomiting (mostly mild to moderate in severity and transient in nature), with few events leading to treatment discontinuation ( Serious TEAEs were reported in 11 (4.9%) and 2 (0.9%) patients in the lixisenatide and placebo groups, respectively. The percentage of patients with TEAEs leading to treatment discontinuation was higher in the lixisenatide group than the placebo group; this difference was attributable mainly to a higher proportion of patients in the lixisenatide group with GI TEAEs leading to discontinuation.
Out of the 5 events sent to the Allergic Reaction Assessment
Committee for adjudication, 1 was positively adjudicated to be an allergic event related to treatment with lixisenatide (Table 3) . Abbreviations: TEAE, treatment-emergent adverse event; ARAC, Allergic Reaction Assessment Committee. a 1 (0.4) patient in the lixisenatide group experienced a serious allergic event (urticaria) that was considered to be related to treatment and discontinued. An additional patient experienced a mild dermatitis, not related to lixisenatide, and was able to complete the study on lixisenatide.
b Symptomatic hypoglycaemia was defined as an event with clinical symptoms that were considered to result from a hypoglycaemic episode with an accompanying plasma glucose of <3.3 mmoI/L; or associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.
c Percent is calculated using the number of safety patients as the denominator.
d Calculated as (number of events, divided by total exposure +3 days in patient-years).
e Severe symptomatic hypoglycaemia was defined as an event with clinical symptoms that were considered to result from hypoglycaemia in which the patient required the assistance of another person, because the patient could not treat themselves due to acute neurological impairment directly resulting from the hypoglycaemic event with an accompanying plasma glucose of <2.0 mmol/L, or if no plasma glucose measurement was available, associated with prompt recovery after oral carbohydrate, intravenous glucose, or glucagon administration.
| Symptomatic hypoglycaemic events
The incidence of protocol-defined symptomatic hypoglycaemia was similar in the two arms ( The clinical efficacy of lixisenatide has been demonstrated previously and it has been shown to be well tolerated while providing overall glycaemic control as a monotherapy or in combination with
OADs and/or BI in the phase III GetGoal trials. 18, 22, 23 In a study enrolling Asian populations with T2D insufficiently controlled with BI and/or sulphonylurea, lixisenatide also significantly improved glycaemic control over 24 weeks. 22 The mean difference for lixisenatide vs placebo in the present study (HbA1c −0.51%) was clinically relevant and extended that seen in the global population of the GetGoal-L trial (HbA1c −0.4%). 18 In contrast to the GetGoal-L trial, in the present study, the established treatment regimen was further improved by a treat-to-target titration on FPG before randomization to identify those patients requiring treatment intensification. Lixisenatide is known to reduce HbA1c in patients with T2D, with a pronounced effect on PPG, and these data confirm these findings through significantly improved 2-hour PPG levels over the 24-week study. As FPG was primarily tackled before randomization via BI titration, and BI was to be kept stable after randomization, it did not notably further improve after randomization.
Previous literature has indicated that PPG is a more important predictor of cardiovascular disease and all-cause mortality than FPG. 24, 25 The significant reductions in 2-hour PPG and plasma glucose excursion shown here were also demonstrated in the GetGoal-L-Asia trial. 22 These post-breakfast glycaemic results are consistent with evidence from other GetGoal trials and are believed to be related to the slowing of gastric emptying by lixisenatide. 26 The weight benefits of GLP-1 RAs make them suitable for diabetes treatment, especially in an overweight patient population or in those taking BI, which can lead to weight gain. 8, 18 In the present study, As GetGoal-L-C was designed to identify the population that really requires further treatment intensification despite optimized BI, the run-in period aimed to optimize the existing BI regimen. After randomization, no further titration of BI was permitted, to allow for the evaluation of lixisenatide under stable background treatment.
Although greater than that achieved with placebo, further titration of BI dose in combination with lixisenatide may have increased the proportion of patients with HbA1c <7%; this would need to be investigated in a different study. Even though patients' glycaemic control with BI was improved during the run-in period, the addition of lixisenatide further reduced HbA1c from baseline in these difficult-to-treat patients (HbA1c ≥7% and ≤9.5%), along with slightly lower BI doses.
The present study, therefore, evaluated a population for whom improving glycaemic control may be expected to be challenging.
In conclusion, adding lixisenatide achieved higher levels of glycaemic control in advanced T2D inadequately controlled with BI with/without metformin, with a beneficial effect on weight, no additional risk of hypoglycaemia, and a tolerability profile consistent with previous data. Lixisenatide may therefore be considered a treatment option for Asian, including Chinese, patients when added to BI in this population, and could possibly help a higher proportion of these patients to meet glycaemic control targets.
